Tudor Investment Corporation »

Peregrine Pharmaceuticals shares owned by Tudor Investment Corporation

Quarter-by-quarter ownership of Peregrine Pharmaceuticals (CDMO) shares owned by Tudor Investment Corporation from 13F filings

Historical chart of Tudor Investment Corporation investment in Peregrine Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Peregrine Pharmaceuticals held by Tudor Investment Corporation consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Peregrine Pharmaceuticals by Tudor Investment Corporation

Quarter filed Position value Share count Share price at filing
2024-03-31 $208k 31k 6.70
2022-06-30 $178k 12k 15.26

More positions owned by Tudor Investment Corporation

Ishares Russell 2000 Etf - US ETP ETF Option Call Option (IWM)
Pioneer Natural Resources Co - US Equity (PXD)
Financial Select Sector Spdr Fund - US ETP ETF Option Call Option (XLF)
Energy Select Sector Spdr Fund - US ETP ETF Option Call Option (XLE)
Meta Platforms Inc - US Equity (META)
Spdr S&P 500 Etf Trust - US ETP Exchange-Traded Fund (SPY)
Utilities Select Sector Spdr Fund - US ETP ETF Option Put Option (XLU)
Humana Inc - US Equity (HUM)
Nvidia Corp - US Equity (NVDA)
Apple Inc - US Equity (AAPL)
Eli Lilly & Co - US Equity Option Call Option (LLY)
Unitedhealth Group Inc - US Equity (UNH)
Advanced Micro Devices Inc - US Equity (AMD)
Micron Technology Inc - US Equity (MU)
Nike Inc - US Class B Equity (NKE)

View all positions for Tudor Investment Corporation

Top funds holding Peregrine Pharmaceuticals

BlackRock
Millennium Management
Vanguard Group
AltraVue Capital
12 West Capital Management
Royal Bank of Canada
Snyder Capital Management
Palisade Capital Management
Citadel Advisors
Point72 Asset Management
Newtyn Management
Wellington Management Company
Geode Capital Management
Morgan Stanley
Punch & Associates Investment Management

View all funds holding Peregrine Pharmaceuticals